Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CAD | P27708 | 1/20 | 0.42 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.36 |
| ▸ | SLC7A11 | Q9UPY5 | 1/20 | 0.36 |
| ▸ | METAP2 | P50579 | 3/20 | 0.36 |
| ▸ | METAP1 | P53582 | 3/20 | 0.36 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.36 |
| ▸ | FNTA | P49354 | 2/20 | 0.35 |
| ▸ | FNTB | P49356 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8644441 | 1.00 | CAD (0.42) | CADACEL3MBTL1CPB2KMT2A | |
| SCHEMBL8642328 | 0.86 | ACE (0.43) | CADACEL3MBTL1CPB2KMT2A | |
| SCHEMBL8642329 | 0.86 | ACE (0.43) | CADACEL3MBTL1CPB2KMT2A | |
| SCHEMBL4400081 | 0.85 | DPP4 (0.49) | CADACEL3MBTL1CPB2KMT2A | |
| SCHEMBL20587887 | 0.85 | DPP4 (0.49) | L3MBTL1KMT2APOLBPTGS1NOD1 | |
| SCHEMBL6010631 | 0.85 | DPP4 (0.49) | L3MBTL1KMT2APOLBPTGS1NOD1 | |
| SCHEMBL4400076 | 0.85 | DPP4 (0.49) | L3MBTL1KMT2APOLBPTGS1NOD1 | |
| SCHEMBL6010639 | 0.85 | DPP4 (0.49) | CADACEL3MBTL1CPB2KMT2A | |
| SCHEMBL8848739 | 0.80 | MMP8 (0.51) | — | |
| SCHEMBL4990411 | 0.80 | CAD (0.44) | CADACEL3MBTL1CPB2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7875268-B2 | The use of certain dimercaptoamides as reducing agents, 2-mercapto-N-(2-mercaptoethyl)acetamide, results in curling that is satisfactoryin terms of intensity and in terms of hold over time; less substantial degradation of the hair fiber compared with the reducing agents of the prior art; permanent waves | L'OREAL S.A. (FR) | 2011-01-25 | — | — | US | claimed |
| EP-1584615-B1 | Use of dimercaptoamides for permanently deforming of keratinic fibres | OREAL (FR) | 2008-05-28 | — | — | EP | claimed |
| US-20060013784-A1 | Novel dimercaptoamides, compositions comprising them as reducing agents, and processes for permanently reshaping keratin fibers therewith | L'OREAL S.A. (FR) | 2006-01-19 | — | — | US | claimed |
| US-7875268-B2 | The use of certain dimercaptoamides as reducing agents, 2-mercapto-N-(2-mercaptoethyl)acetamide, results in curling that is satisfactoryin terms of intensity and in terms of hold over time; less substantial degradation of the hair fiber compared with the reducing agents of the prior art; permanent waves | L'OREAL S.A. (FR) | 2011-01-25 | — | — | US | disclosed |
| US-20060013784-A1 | Novel dimercaptoamides, compositions comprising them as reducing agents, and processes for permanently reshaping keratin fibers therewith | L'OREAL S.A. (FR) | 2006-01-19 | — | — | US | disclosed |
| EP-0778285-B1 | The preparation of protected amines or alkylated amino acids | BASF AG (DE) | 1998-08-26 | — | — | EP | disclosed |
| US-5767290-A | PROTECTION OF AMINE BY A TOCOPHERYL RADICAL; MILD CONDITIONS FOR DEPROTECTING; SYNTHESIS OF OLIGOPEPTIDES | BASF AKTIENGESELLSCHAFT (DE) | 1998-06-16 | — | — | US | disclosed |
| US-5684132-A | DEHYDROHALOGENATION OR DESULFATION AND AMINATION TO ADD TOCOPHEROL GROUPS | BASF AKTIENGSELLSCHAFT (DE) | 1997-11-04 | — | — | US | disclosed |
| EP-0778285-A1 | The preparation of protected amines or alkylated amino acids | BASF AKTIENGESELLSCHAFT (DE) | 1997-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060013784-A1 | Novel dimercaptoamides, compositions comprising them as reducing agents, and processes for permanently reshaping keratin fibers therewith | KRT18, CKAP4, S100A4 | CAD 3840/4885ACE 3872/4885L3MBTL1 4554/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.